Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma

Summary

A multicenter, randomized, prospective clinical study of the efficacy and safety of Orelabrutinib maintenance therapy after Autologous Stem Cell Transplantation (ASCT) in patients with primary central nervous system lymphoma.

Timeline

Start

2021-12-01

Primary completion

2024-05-30

Completion

2025-05-30

Drugs

Indications